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COVID-19 is associated with endothelial activation in the setting of a potent inﬂammatory reaction and a hypercoagulable state. The end result of this thromboinﬂammatory state is an excess in thrombotic events, in particular venous thromboembolism.
Pulmonary embolism (PE) has been of special interest in patients with COVID-19 given
its association with respiratory deterioration, increased risk of intensive care unit
admission, and prolonged hospital stay. The pathophysiology and clinical characteristics of COVID-19-associated PE may differ from the conventional non–COVID-19associated PE. In addition to embolic events from deep vein thrombi, in situ pulmonary
thrombosis, particularly in smaller vascular beds, may be relevant in patients with
COVID-19. Appropriate prevention of thrombotic events in COVID-19 has therefore
become of critical interest. Several changes in viral biology, vaccination, and treatment
management during the pandemic may have resulted in changes in incidence trends.
This review provides an overview of the pathophysiology, epidemiology, clinical
characteristics, and risk factors of COVID-19-associated PE. Furthermore, we brieﬂy
summarize the results from randomized controlled trials of preventive antithrombotic
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therapies in COVID-19, focusing on their ﬁndings related to PE. We discuss the acute
treatment of COVID-19-associated PE, which is substantially similar to the management of conventional non-COVID-19 PE. Ultimately, we comment on the current
knowledge gaps in the evidence and the future directions in the treatment and followup of COVID-19-associated PE, including long-term management, and its possible
association with long-COVID.
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Pathophysiology
The pathogenesis of COVID-19-associated PE is still not
completely understood but encompasses the effects of thromboinﬂammation at the alveolus, pulmonary interstitium, and
pulmonary microvasculature levels.1,2 The SARS-CoV-2 interacts with the type II pneumocytes through several membrane
proteins, including the membrane-bound angiotensin-converting enzyme 2. This interaction can lead to a pneumocyte
activation, production of thromboinﬂammatory cytokines,
platelet activation, NETs formation, and coagulation stimulation, promoting an immune pulmonary intravascular coagulopathy which results in an in situ thrombosis of adjacent
peripheral vasculature (►Fig. 1).19,20 Furthermore, DVT and
subsequent embolism can also lead to COVID-19-associated PE.
In addition to immobility and venous stasis, as well as interaction between inﬂammation and coagulation cascade, patients
with COVID-19 exhibit changes in circulating prothrombotic
factors such as elevated factor VIII, ﬁbrinogen, and hyperviscosity, which are associated with excess risk of thrombosis
(►Fig. 1).21 Although in situ thrombosis can be a speciﬁc
mechanism in patients with COVID-19, both in situ thrombosis
and embolic events can contribute to the overall COVID-19associated PE pathogenesis.

Epidemiology
The reported incidence of COVID-19-associated PE varies
signiﬁcantly among the studies and meta-analyses.22,23
Multiple reasons may explain such variability. First, the
sample size and methodology of the included individual
studies differ signiﬁcantly, from small retrospective case
series to large prospective and dedicated studies.24 Second,
the modality for diagnosis varies from underdiagnosis due to
resource limitations or shortage of personal protective
equipment to identiﬁcation based on clinical suspicion to
systematic screening of patients.25,26 Third, the clinical
status of the patients has been strongly correlated with the
PE incidence. ICU patients had a higher risk of PE than nonICU hospitalized patients; whereas non-hospitalized
patients have a lower risk compared with hospitalized
patients with COVID-19.23 Furthermore, the concomitant
anti-inﬂammatory and prophylactic antithrombotic therapy
may affect the incidence.27,28 Ultimately, most reported data
were collected in 2020, before outbreaks with new variants
such as delta (B.1.617.2) and omicron (B.1.1.529). Less is
known about the risk of PE with these strains.29 A small study
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Coronavirus disease 2019 (COVID-19) is a contagious disease
caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2).1 Although COVID-19 is mainly associated
with respiratory morbidity, patients with COVID-19 have
higher D-dimer levels and an increased risk of thromboembolic events, especially venous thromboembolism (VTE).2,3
VTE can be related to an underlying coagulopathy, endothelial activation, and interalveolar (extravascular) ﬁbrin
deposition. The risk of VTE increases with the severity of
illness, and is higher among hospitalized patients, in particular the critically ill.1,2,4 Given the relation to cardiovascular
risk factors and multimorbidity, an integrated and equitable
approach has been promoted to manage the COVID-19
pandemic.5,6
There are several potential hypotheses for the excess of
thromboembolic events in COVID-19.7 After the SARS-CoV2 entrance through the alveolar pneumocytes, local intense
endothelial activation and a subsequent proinﬂammatory
status ensue.8–11 The production of neutrophil extracellular traps (NETs) may lead to heightened platelet activation
and aggregation, and stimulate coagulation, which clinically manifests as thromboembolic events.1,12 Immobility,
the presence of antiphospholipid antibodies, hypoxia,
inﬂammation, and baseline comorbidities that increase
the risk of thrombosis are among other potential reasons
for the excess risk of thrombosis in COVID-19.13 Added to
this is the clinical and pathophysiological associations
of thrombosis with some vaccines used for preventing
COVID-19.14
Among VTE events, pulmonary embolism (PE) has been
closely related to COVID-19, which has resulted in the term
COVID-19-associated PE. Besides embolism from deep vein
thrombosis (DVT) of lower extremities, another possible
mechanism of PE in this setting is in situ thrombosis in
pulmonary arteries, particularly affecting the distal pulmonary vasculature. This pathophysiology is supported by
results from histopathological and some clinical studies.15,16
The clinical signiﬁcance of PE in patients with COVID-19
cannot be overemphasized as the excess insult on an already
injured respiratory system has the potential for catastrophic
consequences.17,18 Furthermore, the long-term effects and
outcomes are unknown.
In this review, we aim to provide insights into the pathophysiology, epidemiology, prevention, diagnosis, and treatment of COVID-19-associated PE. Ultimately, we will
comment on the current gaps in the evidence and future
research directions.

Fig. 1 Comparison of COVID-19-associated PE and non–COVID-19associated PE. COVID-19-associated PE. Pathophysiology mechanism:
(A) the infection by SARS-CoV-2 produces an intense endothelial
activation of the pneumocytes leading to (B) an intense local
inﬂammatory response by the inﬂammasome, which recruits inﬂammatory cells, (C) and promotes the formation of neutrophil extracellular traps (D) which induce platelet activation and aggregation
with the subsequent in situ thrombosis in the peripheral vasculature.
In severe cases, this phenomenon can be local and systemic. Although
in situ thrombosis is a potentially frequent mechanism in COVID-19associated PE, PE can also be produced by other mechanisms such as
DVT embolization. Non-COVID-19-associated PE (conventional PE) is
more common in (A) patients with immobility who are at risk of
developing (B) lower extremity DVT with a posterior embolization to
main pulmonary arterial branches. Data extracted from a study
analyzing patients treated in the emergency department before
hospital admission; these rates may reﬂect the studied sample
incidence and outcomes rather than the overall population incidence
or outcomes.44 DVT, deep vein thrombosis; IMV, invasive mechanical
ventilation; VTE, venous thromboembolism; CTEPH, chronic thromboembolic pulmonary hypertension; PE, pulmonary embolism.

of patients treated in the emergency department in Utah
suggested that the incidence of COVID-19-associated PE
conﬁrmed by computed tomography with pulmonary angiography (CTPA) is decreasing, possibly secondary to vaccination and the outbreak of new variants.30 A large population
study from Sweden reported that the risk of PE was highest
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among the ﬁrst COVID-19 wave compared with the second
and third, suggesting a decrease in the trends over time.31 On
the other hand, in a multicenter register in the Netherlands,
mortality was reduced by 47% in the second wave. Still, the
thrombotic complication rate remained high and comparable to the ﬁrst wave.32 Nevertheless, these population analyses did not biologically conﬁrm the correlation between
waves and new variants. Ultimately, dedicated large epidemiological studies involving several geographical areas are
needed to determine the actual trends.
The initial reports of COVID-19 cases in China did not
describe PE among the complications but did note increased
levels of D-dimer and abnormal coagulation parameters in
critically ill patients.33,34 However, as the disease spread
around the world, multiple cases associating COVID-19 with
PE were reported.35 These ﬁndings were subsequently conﬁrmed by prospective studies analyzing the clinical and
radiological characteristics of patients with COVID-19.36 In
these studies, COVID-19-associated PE was reported in 13.6
to 16.7% of critically ill patients and 2.2 to 8.3% of hospitalized patients who were not admitted directly to the intensive
care unit (ICU).36–39 A Cochrane systematic review pooling
data from 16 studies estimated that in hospitalized patients
with COVID-19, the weighted mean incidence of PE was
4.3%.22 Another systematic review analyzing 44 studies
found an incidence of 7.8% (95% conﬁdence interval [CI],
2.6–15.3%).23 There is greater uncertainty regarding the PE
rates in outpatients and patients post-discharge with COVID19 because of limited data. A meta-analysis assessing postdischarge rates of PE estimated an incidence of 1.5% (95% CI:
0.5–4.0%)40 at a mean of 68 days of follow-up. However, data
from placebo arms in randomized controlled trials (RCTs) of
outpatients with COVID-19 have found rates of PE at approximately 1% up to 30 days of follow-up.41,42 Results from other
recently completed trials will provide further clarity on this
topic.

Clinical and Radiological Characteristics
Several epidemiological and clinical differences have
been observed between COVID-19-associated PE and non–
COVID-19-associated PE (►Fig. 1). Moreover, some authors
have proposed that COVID-19-associated PE exhibits a
different disease phenotype than conventional non–
COVID-19-associated PE.43 In a Spanish study that included
patients treated in emergency departments before hospitalization, COVID-19-associated PE had a higher incidence
when compared with non–COVID-19-associated PE (310
vs. 35 per 100,000 person-years), representing an almost
ninefold increase in risk.44 Remarkably, these rates may
reﬂect the studied sample incidence rather than the actual
disease incidence in the overall population.
Conventional risk factors for PE are less frequently
observed in patients with COVID-19 compared with nonCOVID-19 era. In the Computerized Registry of Patients with
Venous Thromboembolism (RIETE), patients who had non–
COVID-associated PE (i.e., enrolled before 2018) were predominantly women aged 60 to 70 years with conventional
cardiovascular risk factors,45 whereas patients included
Seminars in Thrombosis & Hemostasis
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during the pandemic in the RIETE registry (March to
May 2020) were predominantly males aged 60, with conventional cardiovascular risk factors.46 In comparison with
patients without COVID-19, patients with COVID-19 had a
higher frequency of immobility (78 vs. 21%) and a lower rate
of coincident surgical procedure (2 vs. 12%), malignancy (4
vs. 22%), or previous VTE events (4 vs. 15%).45,46 Of note,
more than half of patients with COVID-19-associated PE do
not have concomitant DVT.47,48 In contrast to non–COVID19-associated PE, more patients with COVID-19-associated
PE developed PE despite receiving standard-intensity thromboprophylaxis.1 This issue has been the impetus for several
other trials of intensiﬁed prophylactic antithrombotic
therapies.13,49
The anatomical location of COVID-19-associated PE has
been related to different radiological patterns compared
with non–COVID-19-associated PE. COVID-19-associated
PE has been particularly observed in segmental and subsegmental pulmonary arteries, whereas a smaller proportion
of patients, compared with non–COVID-19-associated PE,
have thrombi in the main pulmonary arteries (i.e., central
vasculature).44 These ﬁndings align with the lower frequency
of DVT observed in patients with COVID-19-associated PE
and in situ thrombosis in the distal pulmonary vasculature
on postmortem analyses.15,16,50,51

Risk Stratiﬁcation
In the broad population of patients with COVID-19, several
risk factors have been associated with increased short-term
mortality. These factors include elevated D-dimer, C-reactive protein (CRP), and cardiac troponin I.52 Clinical
characteristics including dementia, diabetes mellitus with
insulin treatment, chronic obstructive pulmonary disease,
peripheral arterial disease, active smoking, chronic liver
disease, and rheumatologic diseases are also associated
with adverse outcomes.52,53 Over 300 prediction models
have been described, but many are of limited utility.54 The
4C Mortality Score has shown a good discrimination for
mortality (C index: 0.77 [95% CI: 0.76–0.77]). It includes
eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate,
peripheral oxygen saturation, level of consciousness, urea
level, and CRP.55 The model has been prospectively
validated.56
Studies assessing risk factors for poor outcomes in
patients with COVID-19-associated PE are limited. Patients
with COVID-19-associated PE may have a higher risk of ICU
admission, mechanical ventilation, and prolonged hospitalizations than patients without PE.44,57 Moreover, a higher
simpliﬁed Pulmonary Embolism Severity Index score and the
presence of right ventricle dysfunction have been related to
an increase in in-hospital mortality.58
Determination of the true impact of COVID-19-associated
PE requires dedicated investigations that have not been
conducted to date. Such analyses would need to take into
account baseline comorbidities but also antithrombotic and
non-antithrombotic cotreatments, as well as immortal time
bias.44,57,59,60
Seminars in Thrombosis & Hemostasis
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Prevention
As a consequence of the limited high-quality evidence early
during the pandemic, most of the recommendations were
based on expert consensus documents and evidence extrapolated from the pre-COVID-19 era and mainly from noninfectious settings such as the conventional PE.61,62 Nevertheless, an
extraordinary worldwide scientiﬁc effort promoted the design
of dozens of RCTs assessing the role of different drug strategies
for preventing VTE in patients with COVID-19.13,49,63,64 Currently, several of these RCTs covering different clinical settings
have reported their primary results. Some were prematurely
stopped due to futility, low recruitment, or logistics issues.65
As the discussion herein primarily focuses on COVID-19-associated PE (►Tables 1–4), additional details for non-PE outcomes can be found in individual records of these trials and
published meta-analyses of the trial results.27,28,66

Outpatients
In the Sulodexide in the Treatment of Early Stages of COVID-19
(SULES-COVID) trial, sulodexide (a primarily oral heparinoid
with endothelial stabilizing and antithrombotic properties67)
was not associated with a signiﬁcant increase in major bleeding (risk ratio [RR]: 3.10, 95% CI: 0.10–76.0). PE event rates
were not reported.68 In the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-4B, apixaban 2.5 mg
BID (0 vs. 0%) or 5 mg BID (0 vs. 0%) was not signiﬁcantly
associated with a reduction in PE compared with placebo.
There were no major bleeding events in the study, but two
(0.7%) clinically relevant nonmajor bleeding in patients treated
with apixaban and no bleeding in the aspirin and placebo
group.41 An RCT focused on the symptoms in high-risk adults
with mild COVID-19 compared the effect of rivaroxaban 10 mg
with placebo for the progression and symptoms resolution.
The investigators reported no PE events.42 The Early Prophylactic Low-Molecular-Weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients (ETHIC) trial included
unvaccinated patients with at least one risk factor for severe
disease.69 Standard-intensity prophylactic anticoagulation
with enoxaparin for 21 days was not signiﬁcantly associated
with a reduction in PE compared with standard of care (RR:
0.36, 95% CI: 0.01–8.78). There were two minor bleeding in
patients treated with enoxaparin and one in the standard of
care group. No major bleeding was observed. The Enoxaparin
for Primary Thromboprophylaxis in Ambulatory Patients With
COVID-19 (OVID) trial included patients older than 50 years
presenting with acute COVID-19 symptoms.70 There was no
signiﬁcant reduction in the PE rate between standard-intensity prophylactic anticoagulation with enoxaparin for 14 days
and standard of care (RR: 0.25, 95% CI: 0.03–2.26). No bleeding
events were reported. The double-blind Study of Rivaroxaban
to Reduce the Risk of Major Venous and Arterial Thrombotic
Events, Hospitalization and Death in Medically Ill Outpatients
With Acute, Symptomatic COVID-19 Infection (PREVENT-HD;
NCT04508023) recently completed enrollment of over 1,000
symptomatic outpatients with laboratory-conﬁrmed COVID19 who had additional risk factors for adverse events and will
compare the effect of rivaroxaban 10 mg once daily versus

Downloaded by: Henry Ford Hospital. Copyrighted material.
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Trial

Design summary

Main findings

PE results

SULES-COVID68

- Single-center, placebo-controlled RCT
comparing sulodexide vs. placebo
- Lead researcher was not blinded to group
allocation
- Primary endpoint: need for hospital
admission for clinical care

- 312 patients randomized; 243 patients
included in the per-protocol analysis
- Sulodexide signiﬁcantly reduced the rate
of hospitalization compared with placebo

- PE rates were not
reported

ACTIV-4B41

- Adaptive, double-blind, placebo-controlled RCT
- Random allocation in a 1:1:1:1 ratio to
aspirin, low-intensity apixaban, full-intensity apixaban, or placebo for 45 d
- Primary endpoint: composite of all-cause
mortality, symptomatic venous or
arterial thromboembolism, MI, stroke, or
hospitalization for cardiovascular or
pulmonary cause

- Study was stopped prematurely, 657 (9%)
of the original sample size were included.
Event rate was lower than expected.
- Aspirin or apixaban compared with
placebo did not signiﬁcantly reduce the
rate of the composite clinical outcome

- There were no PE events

Ananworanich
et al42

- Double-blind, placebo-controlled RCT
comparing rivaroxaban 10 mg vs. placebo
- Primary efﬁcacy endpoint: proportion of
participants who progressed to a moderate
or severe disease category through day 28

- Study was stopped prematurely, 497 (82%)
of the original sample size were included
- Rivaroxaban did not signiﬁcantly reduce the
disease progression in high-risk adults with
mild COVID-19

- There were no PE events

ETHIC69

- Open-label, multicenter, RCT comparing
standard-intensity prophylactic anticoagulation with enoxaparin for 21 d vs.
standard of care
- Primary endpoint: composite of all-cause
hospitalizations and all-cause mortality at
21 d
- Patients were unvaccinated and had at
least one risk factor for severe diseasea

- Study was stopped prematurely, 219
(16%) of the original sample size were
included
- Standard-intensity prophylactic anticoagulation with enoxaparin did not signiﬁcantly improve clinical outcomes
compared with standard of care

- There were no signiﬁcant differences in PE
between standard-intensity prophylactic
anticoagulation and
standard of care (0 vs.
1%; RR: 0.36, 95% CI:
0.01–8.78)

OVID70

- Open-label, multicenter, RCT comparing
standard-intensity prophylactic anticoagulation with enoxaparin for 14 d vs.
standard of care
- Primary endpoint: composite of any untoward hospitalizations and all-cause
mortality at 30 d
- Patients were 50 y or older and presented
with respiratory symptoms or body temperature >37.5 °C

- Study was stopped prematurely, 472
(51%) of the original sample size were
included
- Standard-intensity prophylactic anticoagulation with enoxaparin did not signiﬁcantly improve clinical outcomes
compared with standard of care

- There were no signiﬁcant differences in PE
between standard-intensity prophylactic
anticoagulation and
standard of care (0.4 vs.
2.0%; RR: 0.25, 95% CI:
0.03–2.26)

Abbreviations: PE, pulmonary embolism; RCT, randomized controlled trial; MI, myocardial infarction; RR, risk ratio.
a
Age 70 years, body mass index >25 kg/m2, chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular disease, or corticosteroid use.

placebo for a composite of symptomatic VTE, myocardial
infarction, ischemic stroke, acute limb ischemia, noncentral
nervous system systemic embolization, all-cause hospitalization, and all-cause mortality.71

Hospitalized Noncritically Ill Patients
Most data on COVID-19-associated PE come from studies of
hospitalized patients.1 In the Full Anticoagulation Versus
Prophylaxis in COVID-19 (ACTION) trial, full-intensity prophylactic anticoagulation with rivaroxaban (15 or 20 mg QD)
or heparin did not signiﬁcantly reduce PE (RR: 0.53, 95% CI:
0.21–1.31) and was associated with a signiﬁcant increase in
major or clinically relevant non-major bleeding (RR: 3.64,
95% CI: 1.61–8.27) compared with standard-intensity prophylactic anticoagulation.72 The Comparison of Two Different Doses of Bemiparin in COVID-19 (BEMICOP) and
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard

Care (RAPID) trials evaluated the effect of full-intensity
prophylactic anticoagulation with LMWH or unfractionated
heparin (UFH) compared with standard-intensity prophylactic heparin anticoagulation.73,74 Full-intensity strategy was
not associated with a signiﬁcant difference in major bleeding
in either trial (0 vs. 0%; and RR: 0.52 [95% CI: 0.09–2.85],
respectively). The BEMICOP investigators did not report the
PE event rate. In the RAPID trial, the full-intensity heparin
strategy did not signiﬁcantly reduce the rate of PE compared
with the standard-intensity heparin (RR: 0.21 [95% CI: 0.02–
1.77]). The Comparison of Two Doses of Enoxaparin for
Thromboprophylaxis in Hospitalized COVID-19 Patients (XCOVID trial), which compared intermediate-intensity versus
standard-intensity prophylactic enoxaparin, found a nonsigniﬁcant reduction in PE (RR: 0.08 [95% CI: 0.00–1.36])
without a signiﬁcant effect on major bleeding (RR: 1.01
[95% CI: 0.06–15.92]).75 The Antithrombotic Therapy to
Ameliorate Complications of COVID-19 (ATTACC), ACTIVSeminars in Thrombosis & Hemostasis
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Trial

Design summary

Main findings

PE results

ACTION72

- Open-label, multicenter, RCT comparing full-intensity prophylactic anticoagulation with rivaroxaban
(enoxaparin in patient with contraindication) or standard-intensity.
- Primary outcome: hierarchical analysis
of adjudicated time to death, duration
of hospitalization, or duration of supplemental oxygen to day 30.
- Only patients with elevated D-dimer
were eligible

- 615 patients were included
- Full-intensity prophylactic
anticoagulation with rivaroxaban or enoxaparin followed
by rivaroxaban up to day 30
did not signiﬁcantly improve
clinical outcomes compared
with standard-intensity.

- There were no signiﬁcant differences in PE between fullintensity and standard-intensity prophylactic anticoagulation (2 vs. 4%; RR: 0.53, 95%
CI: 0.21–1.31)

BEMICOP73

- Open-label, multicenter, RCT comparing full-intensity versus standard-intensity prophylactic anticoagulation
with bemiparin
- Primary outcome: composite of death,
ICU admission, need of mechanical
ventilation support, development of
moderate/severe ARDS, and venous or
arterial thrombosis within 10 d of
randomization
- Only patients with elevated D-dimer
were eligible

- Study was stopped prematurely, 65 (39%) of the original
sample size were included.
- Full-intensity bemiparin did
not signiﬁcantly improve
clinical outcomes compared
with standard-intensity prophylactic anticoagulation

- PE rates were not reported

RAPID74

- Open-label, adaptive, RCT comparing
full-intensity prophylactic anticoagulation with heparin vs. standard-intensity.
- Primary endpoint: composite of death,
IMV, non-IMV, or admission to ICU,
assessed up to 28 d
- Only patients with elevated D-dimer
were eligible

- 465 patients were included.
- Full-intensity prophylactic
anticoagulation did not
signiﬁcantly reduce the
primary outcome compared
with standard-intensity but
the odds of death at 28 days
was decreased

- There were no signiﬁcant differences in PE between fullintensity and standard-intensity prophylactic anticoagulation (0.4 vs. 2.1%; RR: 0.21,
95% CI: 0.02–1.77)

Multiplatform trial,
noncritically ill76

- Open-label, adaptive, multiplatform,
RCT comparing full-intensity prophylactic anticoagulation vs. usual care
- Primary endpoint: organ support–free
days, evaluated on an ordinal scale
that combined in-hospital death and
the number of days free of cardiovascular or respiratory organ support up
to day 21

- 2,219 patients were included
- Full-intensity prophylactic anticoagulation signiﬁcantly increased the probability of
survival to hospital discharge
with reduced use of cardiovascular or respiratory organ support (organ support–free days)
compared with usual care

- There were no signiﬁcant
differences in PE between
full-intensity prophylactic
anticoagulation and usual
care (0.8 vs. 1.8%; RR: 0.47,
95% CI: 0.22–1.00)

HEP-COVID77

- Open-label multicenter randomized
active control trial comparing full-intensity prophylactic anticoagulation
with enoxaparin vs. standard- or intermediate-intensity with heparin
- Primary endpoint: composite of VTE,
ATE, or all-cause death at 30 d
- Patients underwent lower extremity
compression ultrasound testing at
hospital day 10 þ 4

- 257 patients were included;
32.8% were admitted to the ICU
- Full-intensity prophylactic anticoagulation with enoxaparin
signiﬁcantly reduced major
thromboembolism and death
compared with standard-intensity prophylactic anticoagulation
- Treatment effect was not seen
in ICU stratum

- There were no signiﬁcant
differences in symptomatic
PE between full-intensity and
standard-intensity prophylactic anticoagulation (3.1 vs.
8.1%; RR: 0.38, 95%
CI: 0.12–1.19)

X COVID75

- Open-label, multicenter, RCT comparing intermediate-intensity prophylactic anticoagulation with enoxaparin vs.
standard-intensity
- Primary endpoint: in-hospital incidence of VTE: asymptomatic or
symptomatic proximal DVT, and/or
symptomatic PE

- Study was stopped prematurely, 189 (7%) of the original
sample size were included
- Intermediate-intensity prophylactic anticoagulation
with enoxaparin was associated with a signiﬁcant reduction of VTE events compared
with a standard-intensity
- There were no DVT events

- Intermediate-intensity
prophylactic anticoagulation
with enoxaparin did not
signiﬁcantly reduced PE compared with standard-intensity
(0.0 vs. 6.5%; RR: 0.08, 95%
CI: 0.00–1.36)

Abbreviations: ARDS, acute respiratory distress syndrome; ATE, arterial thromboembolism; CI, conﬁdence interval; DVT, deep vein thrombosis; ICU,
intensive care unit; IMV, invasive mechanical ventilation; PE, pulmonary embolism; RCT, randomized controlled trial; RR, relative risk; VTE, venous
thromboembolism.
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Table 2 Reported RCTs assessing the role of anticoagulation on COVID-19-associated PE in hospitalized ﬂoor patients
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Trial

Design summary

Main findings

PE results

HESACOVID79

- Open-label, phase II study RCT
comparing full-intensity prophylactic anticoagulation with enoxaparin
vs. standard-intensity
- Primary endpoint: gas exchange
over time through the ratio of
PaO2/FiO2

- 20 patients were included.
- Full-intensity prophylactic anticoagulation with enoxaparin signiﬁcantly improved gas exchange and
decreased the need for mechanical
ventilation in critically ill patients
compared with standard-intensity

- There were no signiﬁcant differences in PE between fullintensity and standard-intensity prophylactic anticoagulation (0 vs. 10.0%; RR: 0.33,
95% CI: 0.02–7.32)

INSPIRATION80

- Open label, multicenter RCT comparing intermediate-intensity prophylactic anticoagulation vs.
standard-intensity
- Primary endpoint: composite of
venous or arterial thrombosis,
treatment with ECMO, or mortality
within 30 d

- 562 patients were included
- Intermediate-intensity prophylactic
anticoagulation, compared with
standard-intensity, did not result in
a signiﬁcant difference in the primary composite outcome

- There were no signiﬁcant differences in PE between intermediate-intensity prophylactic anticoagulation and
standard-intensity (0.7 vs.
1.7%; RR: 0.41, 95% CI: 0.08–
2.12)

Perepu et al82

- Open-label, multicenter RCT comparing intermediate-intensity prophylactic anticoagulation with
enoxaparin vs. standard-intensity
- Primary endpoint: all-cause mortality at 30 d

- 176 patients were included
- Intermediate-intensity prophylactic
anticoagulation with enoxaparin
and standard-intensity did not differ signiﬁcantly in preventing death
or thrombosis at 30 d

- PE rates were not reported

Multiplatform trial,
critically ill84

- Open-label, adaptive, multiplatform, RCT comparing full-intensity
prophylactic anticoagulation with
heparin vs. usual care
- Primary endpoint: organ support–
free days, evaluated on an ordinal
scale that combined in-hospital
death and the number of days free
of cardiovascular or respiratory
organ support up to day 21

- Trial was stopped for futility with
1,098 patients included
- Full-intensity prophylactic anticoagulation with heparin did not result
in a greater probability of survival
to hospital discharge or a greater
number of days free of cardiovascular or respiratory organ support
(organ support–free days) than
usual care

- Full-intensity prophylactic
anticoagulation signiﬁcantly
reduced symptomatic PE
compared with usual care
(2.5 vs. 7.5%; RR: 0.33, 95%
CI: 0.18–0.60)

Swiss
COVID-HEP83

- Open-label, multicenter RCT comparing full-intensity prophylactic
anticoagulation with heparin vs.
usual care
- Primary endpoint: all-cause death,
VTE, arterial thrombosis, and disseminated intravascular coagulopathy, with screening for proximal DVT
- Only patients with elevated D-dimer
were eligible

- Study was stopped prematurely,
159 (79%) of the original sample
size were included
- In 71.7% of the patients, PE was
excluded before inclusion
- Full-intensity prophylactic anticoagulation with heparin was not signiﬁcantly associated with a
reduction in the primary endpoint
compared with usual care

- One event of nonfatal PE with
proximal DVT occurred in the
usual-care group; there were
no events in the full-intensity
group (0 vs. 1.1%; RR: 0.34,
95% CI: 0.01–8.16)

Abbreviations: CI, conﬁdence interval; ECMO, extracorporeal membrane oxygenation; PaO2/FiO2, pressure of arterial oxygen to fractional inspired
oxygen concentration; PE, pulmonary embolism; RCT, randomized controlled trial; RR, relative risk.

4A, and Randomized, Embedded, Multifactorial Adaptive
Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) is the largest reported trial assessing the role of
escalated-intensity prophylactic anticoagulation and usual
care with heparin in non-critically ill patients.76 This multiplatform trial showed a non-signiﬁcant reduction in PE (RR:
0.47, 95% CI: 0.22–1.00) with a non-signiﬁcant increase in
major bleeding (RR: 2.70 [95% CI: 1.00–4.69]). The Full Dose
Heparin versus Prophylactic Or Intermediate Dose Heparin
in High Risk COVID-19 Patients (HEP-COVID) trial found
similar results assessing the role of enoxaparin at fullintensity versus institutional standard- or intermediateintensity prophylactic anticoagulation in patients with a
fourfold elevation of D-dimer.77 Enoxaparin at full intensity,
compared with standard or intermediate intensity, was not
associated with a signiﬁcant reduction in symptomatic PE
(RR: 0.38, [95% CI: 0.12–1.19]) or a signiﬁcant increase in

major bleeding (RR: 2.88 [95% CI: 0.59–14.02]). It should be
noted that none of these trials were powered for PE as the
primary outcome, or for major bleeding events. Therefore,
the lack of signiﬁcant difference may be due to type II error.
Several other RCTs are still ongoing or in the analytical
phase.13 FREEDOM COVID Anticoagulation Strategy Randomized Trial (FREEDOM COVID-19; NCT04512079) is the
largest trial, including more than 3,000 patients, assessing
the effect of escalated-intensity prophylactic anticoagulation
with enoxaparin or apixaban, compared with standardintensity prophylactic enoxaparin, in patients not yet requiring ICU support.78

Hospitalized Critically Ill Patients
Hospitalized patients admitted to the ICU are at a higher risk
of PE.23 The Therapeutic versus Prophylactic Anticoagulation
for Severe COVID-19 (HESA-COVID) trial was a small pilot
Seminars in Thrombosis & Hemostasis
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Table 3 Reported RCTs assessing the role of anticoagulation on COVID-19-associated PE in hospitalized ICU patients
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Table 4 Reported RCTs assessing the role of anticoagulation on COVID-19-associated PE in post-discharge patients
Trial
MICHELLE

85

Design summary

Main findings

PE results

- Open-label, multicenter, RCT
comparing, at hospital discharge,
rivaroxaban 10 mg/day or no
anticoagulation for 35 d
- Primary endpoint: composite of
symptomatic or fatal VTE, asymptomatic VTE, symptomatic ATE, and
cardiovascular death at day 35
- Only patients at increased risk for
VTE were eligible
- Bilateral lower limb venous Doppler
ultrasound and computed tomography pulmonary angiograms were
performed at 35 d

- 320 patients were included
- Thromboprophylaxis with
rivaroxaban 10 mg/day for 35
d reduced the risk of composite primary endpoint compared with no extended
thromboprophylaxis

- There were no differences in PE
between thromboprophylaxis
with rivaroxaban and no
extended thromboprophylaxis
in symptomatic PE (0.6 vs.
1.3%; RR: 0.50, 95% CI: 0.05–
5.46) or fatal PE (0.0 vs. 1.9%;
RR: 0.14, 95% CI: 0.01–2.74)

trial comparing full-intensity prophylactic enoxaparin
versus standard intensity. There were no signiﬁcant differences in PE (RR: 0.33 [95% CI: 0.02–7.32]) or major bleeding
(0 vs. 0%; p ¼ NS).79 The Intermediate vs Standard-Dose
Prophylactic Anticoagulation in Critically-ill Patients With
COVID-19 (INSPIRATION) trial compared intermediate-intensity and standard-intensity prophylactic anticoagulation
with heparin-based regimens. The investigator found no
signiﬁcant differences in PE (RR: 0.41 [95% CI: 0.08–2.12])
or major bleeding (RR: 1.81 [95% CI: 0.54–6.13]) between
groups.80,81 Perepu et al compared the effect of intermediate-intensity prophylactic enoxaparin versus standardintensity prophylactic anticoagulation. The authors did not
report PE event rates, and there was no signiﬁcant increase in
major bleeding (RR: 0.99 [95% CI: 0.14–6.86]).82 The Swiss
Preventing COVID-19 Complications With Low- and Highdose Anticoagulation (COVID-HEP) trial compared fullintensity prophylactic anticoagulation with heparin with
lower-intensity prophylactic anticoagulation; there were
no signiﬁcant differences in the rate of PE (0 vs. 1.1%; RR:
0.34, 95% CI: 0.01–8.16) or major bleeding (1.4 vs. 2.5%; RR:
0.52, 95% CI: 0.05–5.61).83 The largest trial is the ATTACC,
ACTIV-4A, and REMAP-CAP including more than 1,000 critically ill patients.84 Full-intensity prophylactic anticoagulation was associated with a signiﬁcant reduction in PE (RR:
0.33 [95% CI: 0.18–0.60) without a signiﬁcant increase in
major bleeding (RR: 1.63; 95% CI: 0.82–3.25]) compared with
usual care. Nevertheless, this multiplatform RCT did not
reach its primary endpoint (see original trial report and
summary in ►Table 3).84

Meta-Analyses and Systematic Reviews
One systematic review and meta-analysis, including six RCTs
of hospitalized ﬂoor patients and four RCTs of ICU patients,
found a signiﬁcant reduction in the COVID-19-associated PE
in patients treated with escalated-intensity prophylactic
anticoagulation compared with standard-intensity (RR:
0.39, 95% CI: 0.26–0.58). However, escalated-intensity was
associated with a signiﬁcant increase in major bleeding (RR:
Seminars in Thrombosis & Hemostasis
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1.73, 95% CI: 1.15–2.60) and did not signiﬁcantly decrease
all-cause death (RR: 0.96, 95% CI: 0.78–1.18) compared with
standard-intensity. The results were consistent regardless of
the patient clinical status (ﬂoor vs. no ﬂoor).27,28 An interesting observation is that in contrast to conventional PE, in
COVID-19-associated PE, escalated-intensity prophylaxis
anticoagulation was not associated with a risk reduction in
DVT (RR: 1.03, 95% CI: 0.60–1.75), raising the hypothesis that
the underlying thromboinﬂammatory mechanism might
differ between these two entities.27,28 Another systematic
review and meta-analysis analyzing six trials of therapeutic
heparin (three on moderately ill and three on critically ill)
found a signiﬁcant interaction between heparin treatment
intensity and severity of the disease (moderately vs. critically
ill) (PInteraction ¼ 0.034). In moderately ill patients, there was
no signiﬁcant reduction in all-cause death between heparinbased full-intensity prophylactic anticoagulation and standard-intensity (odds ratio [OR]: 0.76, 95% CI: 0.57–1.02), but
signiﬁcant reductions in the composite of death or invasive
mechanical ventilation (OR: 0.77, 95% CI: 0.60–0.98), and
death or any thrombotic event (OR: 0.58, 95% CI: 0.45–0.77)
were observed, without a signiﬁcant increase in bleeding
events. However, in severely ill patients, there was no beneﬁt
of heparin-based full-intensity prophylactic anticoagulation
over standard-intensity.66

Post-Discharge Patients
In the post-discharge patients setting, the Medically Ill
hospitalized Patients for COVID - THrombosis Extended
ProphyLaxis with rivaroxaban ThErapy (MICHELLE) trial
evaluated the role of extended thromboprophylaxis with
rivaroxaban 10 mg compared with the standard of care
in patients with an increased risk of VTE and D-dimer.85 At
1-month follow-up, extended thromboprophylaxis was not
associated with a signiﬁcant reduction in symptomatic pulmonary PE (RR: 0.50, 95% CI: 0.05–5.46) or fatal PE (RR: 0.14,
95% CI: 0.01–2.74), without a signiﬁcant increase in clinically
relevant non-major bleeding (RR: 1.00, 95% CI: 0.14–7.01).
The ongoing ACTIV-4C trial (NCT04650087) will provide
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Abbreviations: ATE, arterial thromboembolism; CI, conﬁdence interval; PE, pulmonary embolism; RCT, randomized controlled trial; RR, relative risk;
VTE, venous thromboembolism.

valuable data on the role of extended thromboprophylaxis
with apixaban 2.5 mg compared with placebo 30 days after
discharge.

Non-Anticoagulant Trials
Some RCTs evaluating drugs targeting thromboinﬂammatory
pathways have also assessed the effects on COVID-19-associated PE. The Randomized Evaluation of COVID-19 Therapy
(RECOVERY) and ACTIV-4B trials evaluated the effect of
aspirin in hospitalized patients and outpatients, respectively.
There were no signiﬁcant differences in PE rates between
patients allocated to antiplatelet versus standard therapy in
both trials.41,86 The REMAP-CAP trial assessed the effect of
aspirin and P2Y12 inhibitors (mostly clopidogrel) in critically
ill patients with COVID-19 and there were no signiﬁcant
differences in the study groups in the incidence of COVID-19associated PE.87 Furthermore, trials assessing the role of antiinﬂammatory, lipid-lowering, or antiviral drugs such as
baricitinib, colchicine, canakinumab, atorvastatin, and
remdesivir did not ﬁnd a signiﬁcant effect of these drugs
on PE rates compared with standard of care or placebo in
hospitalized patients.88–92

Clinical Guidelines
Professional and scientiﬁc organizations have integrated the
current evidence and published clinical guidelines for the
management of antithrombotic therapy in patients with
COVID-19.93–96 These recommendations extend beyond PE,
per se, and include the risk of venous or arterial thrombosis,
organ support, mortality, and bleeding. The recommendations are divided according to the severity of the disease and
outpatient or inpatient settings. In outpatients, the consensus is against routine antithrombotic therapy to prevent PE
or other thrombotic events and against routine continuation
of VTE prophylaxis in unselected patients after hospital
discharge. However, extending thromboprophylaxis can be
considered in patients at high risk for VTE and low risk of
bleeding, similar to patients without COVID-19. Among
inpatients, the recommendations are stratiﬁed according
to the need for ICU and oxygen ﬂow requirements. In patients
who require ICU-level care, including those receiving highﬂow oxygen, standard-intensity prophylactic anticoagulation is recommended by most guideline documents. In
contrast, full-intensity prophylactic anticoagulation for
VTE is considered in carefully selected non-ICU patients.
These include ﬂoor patients who require low-ﬂow oxygen,
elevated D-dimer, and without increased bleeding risk.
Among patients who do not meet these criteria, the recommendation is to use standard-intensity prophylactic anticoagulation with heparin regimens.

Diagnosis
Evaluation of COVID-19-associated PE may be challenging
because PE symptoms can overlap with inherent COVID-19
symptoms, and imaging studies may not be feasible in all
cases, especially those who are critically ill. Nevertheless,
clinicians should be vigilant about the risk of PE in patients
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with COVID-19. Conventional predictive models such as
Padua, International Medical Prevention Registry on Venous
Thromboembolism (IMPROVE), or Caprini can be used to
assess the risk of VTE, particularly in hospitalized patients.1 It
should be highlighted that based on these models, a high
proportion of patients with COVID-19 qualify as a high risk
for VTE due to acute infection, immobilization, respiratory
failure, and elevated D-dimer. However, in an external
validation study, the IMPROVE-DD demonstrated very
good discrimination in identifying hospitalized patients
with COVID-19 at risk of VTE.97 In patients with a low or
moderate pretest probability of PE, a normal D-dimer may be
sufﬁcient to exclude the diagnosis of PE. Similar to preCOVID-19 era, the positive predictive value of D-dimer level
elevation, alone, is not sufﬁciently high to diagnose PE.94
CTPA is the preferred test to conﬁrm or exclude the diagnosis.
Implementing bedside ultrasound (i.e., to evaluate for right
ventricular strain, clot in transit in the heart, or DVT of
extremities) can be helpful in patients who cannot be
transferred for CTPA (i.e., hemodynamically unstable, prone
position, etc.).2 Currently, there is no strong evidence to
support routine screening for PE regardless of their coagulation markers.93 However, retrospective studies have found
that ultra-high D-dimer levels (i.e., >10–20 times fold the
upper limit of normal) in patients with COVID-19 have
been closely associated with COVID-19-associated PE and
increased mortality.98,99 The optimal screening strategy in
patients with COVID-19 and ultra-high D-dimer levels is
unknown.100 Several studies have evaluated the utility of
current PE diagnosis prediction models (i.e., Wells, YEARS,
Geneva, etc.) in patients with COVID-19.101,102 Overall, the
current models have shown a limited discrimination ability
to identify patients with COVID-19-associated PE. The CHOD
(CRP, heart rate, oxygen saturation, D-dimer) score exhibited
the best performance among the current models.102 Furthermore, the number of patients who can be managed without
CTPA is lower than in patients without COVID-19, and the
failure rate (proportion of PE cases in the group of patients
with low probability) is higher than in patients without
COVID-19.100 Of note, developing and validating prediction
tools for patients with COVID-19 that consider speciﬁc
variables such as disease stage, need for ICU stay, and anticoagulation prophylaxis is needed in future. In hospitalized
patients who experience rapid deterioration of pulmonary,
cardiac, or neurological function or sudden, localized loss of
peripheral perfusion, evaluation of thromboembolic disease
should be performed.

Treatment
The management considerations for COVID-19-associated PE
are summarized in ►Fig. 2. Overall, acute treatment does not
differ from the non-COVID-19 patients.103 Therapeutic anticoagulation is appropriate for COVID-19-associated PE,
similar to individuals without COVID-19. Moreover, therapeutic anticoagulation might be considered in select cases
with a high index of suspicion until further diagnostic
tests can be performed.93 Potential drug–drug interactions
Seminars in Thrombosis & Hemostasis
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Fig. 2 Algorithms for prevention, diagnosis and initial treatment, and long-term treatment of COVID-19-associated PE. Prevention. The
algorithm is based on the NIH (National Institutes of Health) COVID-19 treatment guidelines. Details about drug and regimen selection and VTE
risk assessment are deﬁned according to the NIH guidelines. 93 Diagnosis and initial treatment. The algorithm differs from the non–COVID-19associated PE in the feasibility of performing a CTA as the standard gold diagnosis. 103 If the patient can’t be transferred from a CTA assessment
test such as TTE or LE, Doppler can provide bedside evaluation for guiding the decision-making process. In patients in whom any test can be
performed, with a high suspicion or pre-test probability, the current recommendation is to initiate therapeutic anticoagulation. † Criteria
suggesting high bleeding risk as per NIH guidelines are a platelet count <50  109/L, hemoglobin <8 g/dL, the need for dual antiplatelet therapy,
bleeding within the past 30 days that required an emergency department visit or hospitalization, history of a bleeding disorder, or an inherited or
active acquired bleeding disorder.93 ‡PE probability scores to consider are Wells criteria, Geneva score, and Pulmonary Embolism Rule-out
Criteria. ||Currently available guidelines include 2019 European Society of Cardiology guidelines for the diagnosis and management of acute
pulmonary embolism developed in collaboration with the European Respiratory Society 105 and Executive Summary: Antithrombotic Therapy for
VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.132 Long-term treatment. When the treatment can be switched to
oral, a careful assessment of the potential drug–drug interactions between anticoagulants and COVID-19-speciﬁc treatment should be done. A
complete list of drug–drug interaction has been previously reported.7 PE, pulmonary embolism; CTA, CT angiography; TTE, transthoracic
echocardiogram; LE, lower extremity; DVT, deep vein thrombosis; UFH, unfractionated heparin; DOACs, direct oral anticoagulants.

Seminars in Thrombosis & Hemostasis

© 2022. Thieme. All rights reserved.

COVID-19-Associated Pulmonary Embolism

The Unknown: Areas of Uncertainty and
Knowledge Gaps
Although there has been an exponential growth in published
data, there remain several areas of uncertainty, in particular
in the treatment and follow-up of patients with COVID-19associated PE. ►Table 5 summarizes the current gaps in the
evidence and future research directions.

Incidence and Screening
The new SARS-CoV-2 variants (B.1.1.529 and BA.2) have been
associated with higher rates of mild and asymptomatic
disease than previous variants (B.1.617).108 However, it is
unknown if this difference correlates with a decreased risk of
COVID-19-associated PE. Given the higher virulence and
transmissibility of newer variants, a higher number of overall
infected people may lead to a higher number of COVID-19associated PE cases, despite a lower individual risk.
The introduction of COVID-19 vaccines was a point of
inﬂection during the pandemic resulting in a signiﬁcant
decrease in adverse outcomes.109 However, regarding PE,

the effect of vaccination on non–vaccine-related PE rates is
uncertain.110 Preliminary data from the United Kingdom
Biobank have suggested that in patients who develop
COVID-19, a history of full vaccination may be associated
with a signiﬁcantly lower 30-day risk of COVID-19-associated VTE (hazard ratio [HR]: 0.13, 95% CI: 0.06–0.28) compared
with unvaccinated patients. The vaccination status did not
affect the risk of non–COVID-19-associated VTE.111
The current guideline documents recommend against
routine screening for VTE in patients with COVID-19.93 It
remains to be determined whether periodic screening in
carefully selected individuals is of clinical utility.

Pathophysiology
The underlying pathophysiological mechanisms of thrombosis
in COVID-19 have not been completely elucidated. Acquired
antiphospholipid syndrome (APS), via molecular mimicry and
endothelial dysfunction, could plausibly explain thrombogenesis in COVID-19.112,113 The exact biological role of antiphospholipid antibodies in PE events and whether they persist over
time remain unknown. Furthermore, the role of antibodies
related to heparin-induced thrombocytopenia in the COVID-19
thrombosis mechanism and the development of thrombosis
with thrombocytopenia syndrome in association with adenoviral vector-based vaccines are poorly understood. It is similarly
unknown whether NETs, high circulating von Willebrand factor,
and factor VIII are causally implicated in COVID-19 thrombosis.
Further research is needed to determine whether targeting
NETs formation with anti-inﬂammatory therapies (i.e., anticytokine therapy against interleukin-1β, glucocorticoids, or
colchicine) or targeting NETs formation or clearance may
improve patient outcomes.

Prevention
Mechanical thromboprophylaxis is a therapeutic modality
widely used in ICU patients, especially those in whom anticoagulation is contraindicated.114 Some scientiﬁc societies
have recommended mechanical thromboprophylaxis in ICU
COVID-19 patients, but these recommendations are based on
expert opinion and evidence from non-COVID-19 patients.115
The safety and efﬁcacy of mechanical thromboprophylaxis
with or without pharmacological thromboprophylaxis should
be a topic of further research.
Several trial-level meta-analyses of RCTs of escalatedintensity versus standard-intensity prophylactic anticoagulation have been reported.27,28,66 Nevertheless, some trials
are still ongoing or unreported, and comprehensive analyses
of these trials using published and unpublished data are
underway by the World Health Organization (WHO). Furthermore, ongoing independent patient data meta-analysis
can produce more reliable results.116

Treatment
Some clinicians and investigators recommend the measurement of anti-activated factor X (anti-Xa) instead of activated
partial thromboplastin time (aPTT) for titration of the intensity of heparin-based anticoagulation in COVID-19. However,
data from the pre-COVID-19 era have not yet supported the
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between COVID-19 therapies and oral anticoagulants should
be assessed when considering initiating oral anticoagulation.1,7 The treatment with systemic thrombolysis in
selected high-risk patients has been reported in case series
using recombinant tissue plasminogen activator without any
major bleeding event but a mortality rate of more than 40%
(3/7 patients).104 Any treatment with systemic thrombolysis
should be considered in line with the current clinical guidelines.105 In a pilot RCT, low-dose, systemic thrombolytic
therapy with recombinant tissue plasminogen activator
did not improve gas exchange outcomes or organ failure
scores compared with standard-intensity versus full-intensity prophylactic anticoagulation regimens in critically ill
patients.106
COVID-19 is considered a provoking factor for PE. Whether the prothrombotic effect of COVID-19 is enduring remains
unknown. Therefore, the ideal duration of anticoagulation
after COVID-19-associated PE is uncertain. In a small
prospective study of 48 patients, after 6 months of oral
anticoagulation, mostly with direct oral anticoagulants,
there were no recurrent PE events or major bleeding events,
while 3 minor bleeding events were identiﬁed.107 In
contrast, another study suggested that patients who had
COVID-19 could be at risk of PE even at 6 months of follow-up
regardless of initial COVID-19 severity.31 Therefore, it is
unknown if the conventional PE treatment duration can be
extrapolated to COVID-19 patients. Additional analyses from
large registries, including RIETE, are ongoing. To the best of
our knowledge, there are no dedicated randomized trials
assessing the optimal duration of anticoagulation in COVID19-associated PE. However, we consider that the duration of
anticoagulation should be as per the standard of care for
patients without COVID-19, or 3 to 6 months (►Fig. 2). In
selected patients with persistent risk factors and/or high
thrombotic burden, indeﬁnite anticoagulation may be
considered.
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Gap

Comments

Temporal trends in COVID-19-associated PE

- Rates of PE events with new viral variants are unknown
- Role of vaccination for the development of COVID-19associated PE in patients developing breakthrough
infection is uncertain
- Potential effect of non-antithrombotic therapies (such
as antiviral agents and anti-inﬂammatory agents) on PE
event rates is unknown

Role of “screening” among high-risk patients

- Efﬁcacy and cost-effectiveness of routine PE
screening (e.g., by CTPA), either at the time of
admission or routine periodic screening in ICU
patients is unknown

Role of antiphospholipid antibodies in PE pathophysiology and prognosis

- Biological role of antiphospholipid antibodies in
COVID-19-associated hypercoagulability, whether
the antibodies persist, and their potential effects on
PE remain unknown

Role of NETs, vWF, and FVIII in PE pathophysiology
and prognosis

- Determine if NETs, vWF, and FVIII are causally
implicated in the pathophysiology
- Determine if pharmacological interventions targeting NETs may reduce COVID-19-associated PE

Risk
stratiﬁcation

Effect of COVID-19-associated PE on in-hospital
mortality and long-term outcomes

- Data related to potential effect of COVID-19-associated PE on mortality are low quality and uncertain
- Short- and long-term effects of COVID-19-associated
PE on mortality remain unknown

Prevention

Efﬁcacy of mechanical thromboprophylaxis

- Safety and efﬁcacy of mechanical thromboprophylaxis as an add-on to pharmacoprophylaxis are
unknown

- Pooled treatment effect is uncertain
- Speciﬁc treatment effects within subgroups is
uncertain (i.e., sex, age group, or severity of the
disease)
- Speciﬁc treatment effects for comparative effectiveness of detailed treatment regimens are uncertain (i.e., all possible comparisons of different
drugs and doses)

- Study-level meta-analysis from the WHO working
group (CRD42020213461) is ongoing
- Ongoing independent patient data meta-analysis
will provide more reliable data

How to monitor parenteral anticoagulant therapy

- Determine the comparative utility of anti-FXa vs.
aPTT, and optimal algorithms for titrating them

Role of catheter-direct thrombolysis

- Determine the optimal patient selection and efﬁcacy

Optimal method for follow-up, and the ideal
duration of treatment of COVID-19-associated PE

- Optimal duration of treatment is unknown

Relationship of COVID-19-associated PE with long
COVID

- Role of COVID-19-associated PE in the development
of CTEPH and long-COVID is unknown
- Ongoing trials are assessing the role of anticoagulants, statins, and other agents for improving Long
COVID-19 symptoms: HEAL-COVID (NCT04801940),
PROVID-LD (NCT05080244), SOLIDARITY
(NCT05220280), NCT04900961, and NCT04978259

Incidence and
screening

Pathophysiology

Treatment

Follow-up

Abbreviations: Anti-FXa, anti-activated factor X; aPTT, activated partial thromboplastin time; CTEPH, chronic thromboembolic pulmonary
hypertension; CTPA, computed tomography with pulmonary angiography; FVIII, factor VIII; ICU, intensive care unit; NET, neutrophil extracellular
traps; PE, pulmonary embolism; US, ultrasound; vWF, von Willebrand factor; WHO, World Health Organization.

superiority of anti-Xa testing.117 Nevertheless, the nonspeciﬁc binding of UFH in a high inﬂammatory setting and the
unreliability of the aPTT due to high FVIII and ﬁbrinogen in
patients with COVID-19 are facts against the use of aPTT
testing.1,118 In the case of measuring the effect of LMWH or
UFH, anti-Xa testing seems to be a preferable strategy,
although it requires further validation in prospective studies.
Seminars in Thrombosis & Hemostasis
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Currently, dexamethasone, interleukin-6 inhibitors (i.e.,
sarilumab and tocilizumab), and Janus kinase inhibitors (i.e.,
baricitinib and tofacitinib) are anti-inﬂammatory therapies
with proven or potential efﬁcacy for treating hospitalized
patients with COVID-19. It is uncertain if these drugs can
affect PE occurrence by modulating thromboinﬂammation.
In the main trials assessing the role of dexamethasone,
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Follow-up
The long-term effects of COVID-19 are not entirely understood and are the topic of ongoing research.125–127 Furthermore, the optimal follow-up for COVID-19-associated PE is
unknown. In particular, there are limited data on the timing,
dedicated workup, optimal method in terms of imaging, and
type and duration of the antithrombotic therapy after the
diagnosis of COVID-19-associated PE.
The WHO deﬁnes long COVID as a condition in individuals
with a history of probable or conﬁrmed COVID-19, usually at
least 3 months after infection onset, with symptoms that last
for at least 2 months and cannot be explained by an alternative disease.128 Its estimated prevalence varies with the age
group, disease severity, and type of persistent symptom but
can range from 10 to 71%.12,129,130 Among its more common
symptoms, there are several respiratory symptoms such as
fatigue (58%), dyspnea (24%), polypnea (21%), and cough
(19%). It is unclear how the micro- and macrothrombotic
pulmonary events could be related to the long COVID-19
symptoms. However, the fact that the COVID-19-associated
PE entails a severe vascular condition in addition to the
parenchymal viral affection could explain the presence of
the multiple respiratory manifestations of long COVID.
Moreover, the relative frequency of chronic thromboembolic
pulmonary hypertension (CTEPH) and its association with
long COVID remains to be determined in patients with
COVID-19-associated PE.131
Patients who survive COVID-19 have an increased 1-year
risk of cardiovascular adverse events, regardless of the
disease severity.127 Therefore, developing models to stratify
patients at high risk of adverse events during follow-up
would help select patients in whom a comprehensive workup can be cost-effective. Moreover, determining the effect of
COVID-19-associated PE on long-term clinical outcomes such
as mortality, long COVID, CTEPH, and other adverse events
warrants further attention.

Further research is needed to clarify its true prognostic
signiﬁcance on fatal and nonfatal outcomes. Major scientiﬁc
organizations provide conditional recommendations in favor of
full-intensity over standard-intensity prophylactic anticoagulation in noncritically ill hospitalized patients with COVID-19
who have a low risk of bleeding. Although treatment of acute
COVID-19-associated PE is generally similar to pre-COVID-19
management, careful attention must be given to potential
drug–drug interactions between COVID-19 therapies and oral
anticoagulants. The optimal type and duration of anticoagulation, long-term effects of COVID-19-associated PE on mortality
or CTEPH, and the relationship with long COVID will require
future investigation.
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Conclusions
COVID-19-associated PE has some speciﬁc clinical characteristics compared with conventional non–COVID-19-associated
PE, suggesting it can include a different disease phenotype.
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